» Articles » PMID: 23291219

Regulation of Erythropoiesis by Hypoxia-inducible Factors

Overview
Journal Blood Rev
Publisher Elsevier
Specialty Hematology
Date 2013 Jan 8
PMID 23291219
Citations 301
Authors
Affiliations
Soon will be listed here.
Abstract

A classic physiologic response to systemic hypoxia is the increase in red blood cell production. Hypoxia-inducible factors (HIFs) orchestrate this response by inducing cell-type specific gene expression changes that result in increased erythropoietin (EPO) production in kidney and liver, in enhanced iron uptake and utilization and in adjustments of the bone marrow microenvironment that facilitate erythroid progenitor maturation and proliferation. In particular HIF-2 has emerged as the transcription factor that regulates EPO synthesis in the kidney and liver and plays a critical role in the regulation of intestinal iron uptake. Its key function in the hypoxic regulation of erythropoiesis is underscored by genetic studies in human populations that live at high-altitude and by mutational analysis of patients with familial erythrocytosis. This review provides a perspective on recent insights into HIF-controlled erythropoiesis and iron metabolism, and examines cell types that have EPO-producing capability. Furthermore, the review summarizes clinical syndromes associated with mutations in the O(2)-sensing pathway and the genetic changes that occur in high altitude natives. The therapeutic potential of pharmacologic HIF activation for the treatment of anemia is discussed.

Citing Articles

L-Arginine and Nitric Oxide in Vascular Regulation-Experimental Findings in the Context of Blood Donation.

Kurhaluk N, Tkaczenko H Nutrients. 2025; 17(4).

PMID: 40004994 PMC: 11858268. DOI: 10.3390/nu17040665.


Microenvironmental dynamics in steady-state and stress erythropoiesis.

Yang C, Suda T Blood Sci. 2025; 7(1):e00219.

PMID: 39949502 PMC: 11822345. DOI: 10.1097/BS9.0000000000000219.


Highlights on U.S. FDA-approved halogen-containing drugs in 2024.

Ali S, Tian X, Meccia S, Zhou J Eur J Med Chem. 2025; 287:117380.

PMID: 39947048 PMC: 11846695. DOI: 10.1016/j.ejmech.2025.117380.


Effects of Nickel Bioaccumulation on Hematological, Biochemical, Immune Responses, Neuroinflammatory, Oxidative Stress Parameters, and Neurotoxicity in Rats.

El Brouzi M, Adadi N, Lamtai M, Boulahfa H, Zghari O, Fath N Biol Trace Elem Res. 2025; .

PMID: 39891830 DOI: 10.1007/s12011-025-04528-x.


Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions.

Belenichev I, Popazova O, Bukhtiyarova N, Ryzhenko V, Pavlov S, Suprun E Antioxidants (Basel). 2025; 14(1).

PMID: 39857442 PMC: 11760872. DOI: 10.3390/antiox14010108.


References
1.
Magnanti M, Gandini O, Giuliani L, Gazzaniga P, Marti H, Gradilone A . Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood. 2001; 98(9):2872-4. DOI: 10.1182/blood.v98.9.2872. View

2.
Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth M . Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41(4):478-81. DOI: 10.1038/ng.320. View

3.
Moore L, Niermeyer S, Zamudio S . Human adaptation to high altitude: regional and life-cycle perspectives. Am J Phys Anthropol. 1999; Suppl 27:25-64. DOI: 10.1002/(sici)1096-8644(1998)107:27+<25::aid-ajpa3>3.0.co;2-l. View

4.
Ravi R, Mookerjee B, Bhujwalla Z, Sutter C, Artemov D, Zeng Q . Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14(1):34-44. PMC: 316350. View

5.
Besarab A, Frinak S, Yee J . What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?. Adv Chronic Kidney Dis. 2009; 16(2):131-42. DOI: 10.1053/j.ackd.2008.12.007. View